OncoMatch/Clinical Trials/NCT06298968
Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma
Is NCT06298968 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies combined therapy using gemcitabine and cisplatin chemotherapy, Lenvatinib and Adebrelimab for intrahepatic cholangiocarcinoma.
Treatment: combined therapy using gemcitabine and cisplatin chemotherapy, Lenvatinib and Adebrelimab — In this phase 2 study, the investigators aim to evaluate the efficacy and safety of combined therapy using gemcitabine and cisplatin chemotherapy, Lenvatinib and Adebrelimab for patients with advanced and unresectable intrahepatic cholangiocarcinoma
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Cholangiocarcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: anti-PD-1 therapy
previous treatment with PD1 antibody
Cannot have received: anti-PD-L1 therapy
previous treatment with programmed death ligand -1 （PD-L1） antibody
Cannot have received: anti-CTLA-4 therapy
previous treatment with cytotoxic T lymphocyte-associated antigen-4 （CTLA4） antibody
Lab requirements
Blood counts
Neutrophils ≥1.5*10^9/L; platelets≥100*10^9/L; hemoglobin≥9g/dl; serum albumin≥3g/dl
Kidney function
serum creatinine ≤ 1.5 ULN, creatinine clearance rate ≥ 60ml / min
Liver function
bilirubin ≤ 2 times ULN; ALT and AST ≤ 2 times ULN
Functional indicators of vital organs meet the following requirements a Neutrophils ≥1.5*109/L; platelets≥100*109/L; hemoglobin≥9g/dl; serum albumin≥3g/dl; b Thyroid stimulating hormone (TSH) ≤ 1 times the upper limit of normal value(ULN), T3, T4 are in the normal range; c bilirubin ≤ 2 times ULN; Alanine aminotransferase （ALT） and Aspartate aminotransferase （AST） ≤ 2 times ULN; serum creatinine ≤ 1.5 ULN, creatinine clearance rate ≥ 60ml / min;
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06298968 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-PD-1 therapy, anti-PD-L1 therapy, anti-CTLA-4 therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages